Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis

Twenty-four patients with bi-allelic familial hypercholesterolemia commencing chronic lipoprotein apheresis (LA) at a mean age of 8.5 ± 3.1 years were analysed retrospectively and in part prospectively with a mean follow-up of 17.2 ± 5.6 years. Mean age at diagnosis was 6.3 ± 3.4 years. Untreated me...

Full description

Saved in:
Bibliographic Details
Main Authors: Taylan, Christina (Author) , Driemeyer, Joenna (Author) , Schmitt, Claus P. (Author) , Pape, Lars (Author) , Büscher, Rainer (Author) , Galiano, Matthias (Author) , König, Jens (Author) , Schürfeld, Carsten (Author) , Spitthöver, Ralf (Author) , Versen, Axel (Author) , Koziolek, Michael (Author) , Marsen, Tobias A. (Author) , Stein, Holger (Author) , Schaefer, Juergen R. (Author) , Heibges, Andreas (Author) , Klingel, Reinhard (Author) , Oh, Jun (Author) , Weber, Lutz T. (Author) , Klaus, Günter (Author)
Format: Article (Journal)
Language:English
Published: 16 September 2020
In: The American journal of cardiology
Year: 2020, Volume: 136, Issue: 12, Pages: 38-48
ISSN:1879-1913
DOI:10.1016/j.amjcard.2020.09.015
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.amjcard.2020.09.015
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0002914920309528
Get full text
Author Notes:Christina Taylan, MD, Joenna Driemeyer, MD, Claus P. Schmitt, MD, Lars Pape, MD, Rainer Büscher, MD, Matthias Galiano, MD, Jens König, MD, Carsten Schürfeld, MD, Ralf Spitthöver, MD, Axel Versen, MD, Michael Koziolek, MD, Tobias A. Marsen, MD, Holger Stein, MD, Juergen R. Schaefer, MD, Andreas Heibges, PhD, Reinhard Klingel, MD, Jun Oh, MD, Lutz T. Weber, MD, and Günter Klaus, MD

MARC

LEADER 00000caa a2200000 c 4500
001 178850612X
003 DE-627
005 20230426162737.0
007 cr uuu---uuuuu
008 220204s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.amjcard.2020.09.015  |2 doi 
035 |a (DE-627)178850612X 
035 |a (DE-599)KXP178850612X 
035 |a (OCoLC)1341441290 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Taylan, Christina  |d 1972-  |e VerfasserIn  |0 (DE-588)131533126  |0 (DE-627)707656648  |0 (DE-576)298568233  |4 aut 
245 1 0 |a Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis  |c Christina Taylan, MD, Joenna Driemeyer, MD, Claus P. Schmitt, MD, Lars Pape, MD, Rainer Büscher, MD, Matthias Galiano, MD, Jens König, MD, Carsten Schürfeld, MD, Ralf Spitthöver, MD, Axel Versen, MD, Michael Koziolek, MD, Tobias A. Marsen, MD, Holger Stein, MD, Juergen R. Schaefer, MD, Andreas Heibges, PhD, Reinhard Klingel, MD, Jun Oh, MD, Lutz T. Weber, MD, and Günter Klaus, MD 
264 1 |c 16 September 2020 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 03.03.2022 
520 |a Twenty-four patients with bi-allelic familial hypercholesterolemia commencing chronic lipoprotein apheresis (LA) at a mean age of 8.5 ± 3.1 years were analysed retrospectively and in part prospectively with a mean follow-up of 17.2 ± 5.6 years. Mean age at diagnosis was 6.3 ± 3.4 years. Untreated mean LDL-C concentrations were 752 mg/dl ± 193 mg/dl (19.5 mmol/l ± 5.0 mmol/l). Multimodal lipid lowering therapy including LA resulted in a mean LDL-C concentration of 184 mg/dl (4.8 mmol/l), which represents a 75.5% mean reduction. Proprotein convertase subtilisin/kexin type 9-antibodies contributed in 3 patients to LDL-C lowering with 5 patients remaining to be tested. After commencing chronic LA, 16 patients (67%) remained clinically stable with only subclinical findings of atherosclerotic cardiovascular disease (ASCVD), and neither cardiovascular events, nor need for vascular interventions or surgery. In 19 patients (79%), pathologic findings were detected at the aortic valve (AV), which in the majority were mild. AV replacement was required in 2 patients. Mean Lipoprotein(a) concentration was 42.4 mg/dl, 38% had >50 mg/dl. There was no overt correlation of AV pathologies with other ASCVD complications, or Lipoprotein(a) concentration. Physicochemical elimination of LDL particles by LA appears indispensable for patients with bi-allelic familial hypercholesterolemia and severe hypercholesterolemia to maximize the reduction of LDL-C. In conclusion, in this rare patient group regular assessment of both the AV, as well as all arteries accessible by ultrasound should be performed to adjust the intensity of multimodal lipid lowering therapy with the goal to prevent ASCVD events and aortic surgery. 
700 1 |a Driemeyer, Joenna  |e VerfasserIn  |4 aut 
700 1 |a Schmitt, Claus P.  |e VerfasserIn  |0 (DE-588)1030179123  |0 (DE-627)734893620  |0 (DE-576)377990280  |4 aut 
700 1 |a Pape, Lars  |e VerfasserIn  |4 aut 
700 1 |a Büscher, Rainer  |e VerfasserIn  |4 aut 
700 1 |a Galiano, Matthias  |e VerfasserIn  |4 aut 
700 1 |a König, Jens  |e VerfasserIn  |4 aut 
700 1 |a Schürfeld, Carsten  |e VerfasserIn  |4 aut 
700 1 |a Spitthöver, Ralf  |e VerfasserIn  |4 aut 
700 1 |a Versen, Axel  |e VerfasserIn  |4 aut 
700 1 |a Koziolek, Michael  |e VerfasserIn  |4 aut 
700 1 |a Marsen, Tobias A.  |e VerfasserIn  |4 aut 
700 1 |a Stein, Holger  |e VerfasserIn  |4 aut 
700 1 |a Schaefer, Juergen R.  |e VerfasserIn  |4 aut 
700 1 |a Heibges, Andreas  |e VerfasserIn  |4 aut 
700 1 |a Klingel, Reinhard  |e VerfasserIn  |4 aut 
700 1 |a Oh, Jun  |e VerfasserIn  |4 aut 
700 1 |a Weber, Lutz T.  |e VerfasserIn  |4 aut 
700 1 |a Klaus, Günter  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t The American journal of cardiology  |d Amsterdam [u.a.] : Elsevier, 1958  |g 136(2020), 12, Seite 38-48  |h Online-Ressource  |w (DE-627)320596249  |w (DE-600)2019595-3  |w (DE-576)10963392X  |x 1879-1913  |7 nnas  |a Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis 
773 1 8 |g volume:136  |g year:2020  |g number:12  |g pages:38-48  |g extent:11  |a Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis 
856 4 0 |u https://doi.org/10.1016/j.amjcard.2020.09.015  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S0002914920309528  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220204 
993 |a Article 
994 |a 2020 
998 |g 1030179123  |a Schmitt, Claus P.  |m 1030179123:Schmitt, Claus P.  |d 910000  |d 910500  |d 50000  |e 910000PS1030179123  |e 910500PS1030179123  |e 50000PS1030179123  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 3 
999 |a KXP-PPN178850612X  |e 4051268195 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Taylan, Christina","family":"Taylan","role":"aut","given":"Christina"},{"family":"Driemeyer","role":"aut","display":"Driemeyer, Joenna","given":"Joenna"},{"family":"Schmitt","role":"aut","display":"Schmitt, Claus P.","given":"Claus P."},{"display":"Pape, Lars","family":"Pape","role":"aut","given":"Lars"},{"given":"Rainer","display":"Büscher, Rainer","family":"Büscher","role":"aut"},{"given":"Matthias","role":"aut","family":"Galiano","display":"Galiano, Matthias"},{"display":"König, Jens","role":"aut","family":"König","given":"Jens"},{"display":"Schürfeld, Carsten","family":"Schürfeld","role":"aut","given":"Carsten"},{"display":"Spitthöver, Ralf","family":"Spitthöver","role":"aut","given":"Ralf"},{"role":"aut","family":"Versen","display":"Versen, Axel","given":"Axel"},{"given":"Michael","role":"aut","family":"Koziolek","display":"Koziolek, Michael"},{"family":"Marsen","role":"aut","display":"Marsen, Tobias A.","given":"Tobias A."},{"given":"Holger","role":"aut","family":"Stein","display":"Stein, Holger"},{"family":"Schaefer","role":"aut","display":"Schaefer, Juergen R.","given":"Juergen R."},{"given":"Andreas","role":"aut","family":"Heibges","display":"Heibges, Andreas"},{"display":"Klingel, Reinhard","role":"aut","family":"Klingel","given":"Reinhard"},{"role":"aut","family":"Oh","display":"Oh, Jun","given":"Jun"},{"given":"Lutz T.","family":"Weber","role":"aut","display":"Weber, Lutz T."},{"display":"Klaus, Günter","family":"Klaus","role":"aut","given":"Günter"}],"note":["Gesehen am 03.03.2022"],"language":["eng"],"origin":[{"dateIssuedDisp":"16 September 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Christina Taylan, MD, Joenna Driemeyer, MD, Claus P. Schmitt, MD, Lars Pape, MD, Rainer Büscher, MD, Matthias Galiano, MD, Jens König, MD, Carsten Schürfeld, MD, Ralf Spitthöver, MD, Axel Versen, MD, Michael Koziolek, MD, Tobias A. Marsen, MD, Holger Stein, MD, Juergen R. Schaefer, MD, Andreas Heibges, PhD, Reinhard Klingel, MD, Jun Oh, MD, Lutz T. Weber, MD, and Günter Klaus, MD"]},"recId":"178850612X","id":{"doi":["10.1016/j.amjcard.2020.09.015"],"eki":["178850612X"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"11 S."}],"title":[{"title_sort":"Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis","title":"Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis"}],"relHost":[{"title":[{"subtitle":"official journal of the American College of Cardiology","title_sort":"American journal of cardiology","title":"The American journal of cardiology"}],"id":{"zdb":["2019595-3"],"eki":["320596249"],"issn":["1879-1913"]},"disp":"Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresisThe American journal of cardiology","origin":[{"publisher":"Elsevier","publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1958","dateIssuedDisp":"1958-"}],"corporate":[{"display":"American College of Cardiology","role":"isb"}],"pubHistory":["1.1958 -"],"note":["Gesehen am 22.12.10","Ungezählte Beil.: Supplement"],"part":{"text":"136(2020), 12, Seite 38-48","volume":"136","extent":"11","year":"2020","pages":"38-48","issue":"12"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320596249","type":{"bibl":"periodical","media":"Online-Ressource"},"name":{"displayForm":["ed.-in-chief Simon Dack"]},"language":["eng"]}]} 
SRT |a TAYLANCHRICARDIOVASC1620